Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL

Key clinical point: For patients with chronic lymphocytic leukemia who have discontinued venetoclax, the best next therapy may depend on prior novel-agent exposure and reasons for discontinuation.

Major finding: The most effective therapies in the postvenetoclax setting included use of a Bruton tyrosine kinase inhibitor in BTK inhibitor–naive or previously responsive patients, and allogeneic transplant following double novel-agent exposure.

Study details: A retrospective, international, 31-center study that including 326 patients treated with venetoclax who discontinued for any reason.

Disclosures: Dr. Mato reported disclosures related to Gilead, AstraZeneca, AbbVie, Sunesis, Johnson & Johnson, TG Therapeutics, LOXO, DTRM Biopharma, Genentech, Janssen, Acerta Pharma, Pharmacyclics, and Celgene.


Mato AR et al. ASH 2019, Abstract 502.